At AAN 2026, Argenx announced positive results from the Phase III, double-blind, placebo-controlled, ADAPT SERON study of Vyvgart.

At AAN 2026, Cabaletta Bio announced positive results from the Phase I/II open-label, RESET-MG study of rese-cel in patients with gMG.

Approval for Xeltis’s aXess device was based on pivotal trial data that demonstrated 79% secondary patency and a patency-related reintervention rate of 1.3 per patient year.

Currently in Phase I development, TherVacB is a therapeutic vaccine candidate designed as an immune therapy for chronic hepatitis B patients.

Roche has reported new findings from the Phase III METEOROID trial of Enspryng in adults and adolescents with MOGAD.

Paradigm's SPIRE is designed to allow more routine care providers in community and rural settings to participate in post-marketing studies.

AstraZeneca will submit the new COPD trial data to regulatory authorities. Credit: Robert Way / Shutterstock.com AstraZeneca’s tozorakimab has shown benefit in a third Phase III trial in chronic ...

Novo Nordisk will be happy with the results after Pfizer has dropped two SCD assets in recent years. Credit: JHVEPhoto / Shutterstock.com A Phase III trial of Novo Nordisk’s once-daily tablet has met ...

Agenus has reported results from a Phase II trial, evaluating the combination of BOT, BAL, and agenT-797 alongside ramucirumab and paclitaxel, in advanced PD-1 refractory gastroesophageal ...

Trump's executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.

Acerand Therapeutics has reported updated findings from its first-in-human Phase I/II study of ACE-106 to treat advanced solid tumours.

Vir Biotechnology has dosed the first patient in one of three expansion cohorts in its ongoing Phase I clinical trial of VIR-5500 for metastatic prostate cancer.